Simultaneous Infection With Porcine Reproductive and Respiratory Syndrome and Influenza Viruses Abrogates Clinical Protection Induced by Live Attenuated Porcine Reproductive and Respiratory Syndrome Vaccination.
Animals
Antibodies, Viral
/ biosynthesis
Coinfection
/ immunology
Cytokines
/ biosynthesis
Datasets as Topic
Dogs
Female
Influenza A Virus, H3N2 Subtype
/ immunology
Madin Darby Canine Kidney Cells
Orthomyxoviridae Infections
/ complications
Porcine Reproductive and Respiratory Syndrome
/ prevention & control
Porcine respiratory and reproductive syndrome virus
/ immunology
Swine
Vaccination
/ veterinary
Vaccine Efficacy
Vaccines, Attenuated
/ immunology
Viral Load
Viral Vaccines
/ immunology
Viremia
/ prevention & control
co-infection
live attenuated vaccine
pig
porcine reproductive and respiratory syndrome virus
swine influenza A virus
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
08
2021
accepted:
21
10
2021
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
15
2
2022
Statut:
epublish
Résumé
The porcine respiratory disease complex (PRDC) is responsible for significant economic losses in the pig industry worldwide. Porcine reproductive and respiratory syndrome virus (PRRSV) and swine influenza virus are major viral contributors to PRDC. Vaccines are cost-effective measures for controlling PRRS, however, their efficacy in the context of co-infections has been poorly investigated. In this study, we aimed to determine the effect of PRRSV-2 and swine influenza H3N2 virus co-infection on the efficacy of PRRSV modified live virus (MLV) vaccination, which is widely used in the field. Following simultaneous challenge with contemporary PRRSV-2 and H3N2 field isolates, we found that the protective effect of PRRS MLV vaccination on clinical disease and pathology was abrogated, although viral load was unaffected and antibody responses were enhanced. In contrast, co-infection in non-immunized animals reduced PRRSV-2 viremia and H3N2 virus load in the upper respiratory tract and potentiated T cell responses against both PRRSV-2 and H3N2 in the lung. Further analysis suggested that an upregulation of inhibitory cytokines gene expression in the lungs of vaccinated pigs may have influenced responses to H3N2 and PRRSV-2. These findings provide important insights into the effect of viral co-infections on PRRS vaccine efficacy that may help identify more effective vaccination strategies against PRDC in the field.
Identifiants
pubmed: 34858411
doi: 10.3389/fimmu.2021.758368
pmc: PMC8632230
doi:
Substances chimiques
Antibodies, Viral
0
Cytokines
0
Vaccines, Attenuated
0
Viral Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
758368Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/R01275X/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/I/00007031
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/I/00007037
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/I/00007039
Pays : United Kingdom
Informations de copyright
Copyright © 2021 Chrun, Maze, Vatzia, Martini, Paudyal, Edmans, McNee, Manjegowda, Salguero, Wanasen, Koonpaew, Graham and Tchilian.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Invest. 2015 Jul 1;125(7):2631-45
pubmed: 26011643
Infect Genet Evol. 2018 Dec;66:111-119
pubmed: 30261264
Front Immunol. 2021 Mar 09;12:637613
pubmed: 33767705
Transl Anim Sci. 2020 May 21;4(2):txaa068
pubmed: 32705063
Virus Res. 2010 Dec;154(1-2):104-13
pubmed: 20837070
Vet Res. 2020 May 13;51(1):66
pubmed: 32404209
mSphere. 2021 Jun 30;:e0117020
pubmed: 34190586
Virol J. 2014 Sep 24;11:170
pubmed: 25253051
J Immunol. 2016 Jun 15;196(12):5014-23
pubmed: 27183611
Arch Virol. 2013 May;158(5):943-53
pubmed: 23232748
J Immunol. 2015 Jul 1;195(1):203-9
pubmed: 26026054
Virology. 2002 Oct 10;302(1):9-20
pubmed: 12429512
Vet Res. 2019 Feb 28;50(1):17
pubmed: 30819249
Front Vet Sci. 2020 Sep 22;7:647
pubmed: 33195504
Transbound Emerg Dis. 2016 Jun;63(3):285-95
pubmed: 25382098
Mucosal Immunol. 2016 Jul;9(4):835-49
pubmed: 26530136
Vaccines (Basel). 2021 Apr 07;9(4):
pubmed: 33917103
Vaccine. 2006 Mar 24;24(14):2634-42
pubmed: 16406169
J Immunol. 2021 Feb 1;206(3):652-663
pubmed: 33328212
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
pubmed: 12184808
Viruses. 2017 Jun 13;9(6):
pubmed: 28608816
J Vet Intern Med. 2020 Sep;34(5):1903-1913
pubmed: 32618394
Virology. 2018 Apr;517:177-187
pubmed: 29402432
Front Immunol. 2021 Feb 02;11:604913
pubmed: 33603740
J Virol. 2012 Jun;86(12):6792-803
pubmed: 22491469
Vet Microbiol. 2018 Mar;216:13-19
pubmed: 29519507
Front Immunol. 2019 Apr 25;10:860
pubmed: 31105695
Vet Microbiol. 1997 Apr;55(1-4):259-64
pubmed: 9220621
Vaccine. 2021 May 21;39(22):3053-3066
pubmed: 33637387
Front Immunol. 2019 Nov 08;10:2625
pubmed: 31787986
J Vet Diagn Invest. 2012 Mar;24(2):349-54
pubmed: 22379051
Vet Microbiol. 2017 Sep;209:13-19
pubmed: 28554869
Dev Comp Immunol. 2014 Jul;45(1):97-106
pubmed: 24561103
Vet Microbiol. 2014 Nov 7;174(1-2):127-38
pubmed: 25301281
Arch Virol. 2021 Sep;166(9):2633-2648
pubmed: 34231026
Clin Vaccine Immunol. 2007 Mar;14(3):269-75
pubmed: 17215336
BMC Vet Res. 2018 Apr 19;14(1):133
pubmed: 29673363
J Immunol. 2020 Aug 1;205(3):648-660
pubmed: 32591390
Vet Res. 2020 Jun 16;51(1):80
pubmed: 32546263
Virology. 2010 Oct 25;406(2):270-9
pubmed: 20701940
Curr Top Microbiol Immunol. 2013;370:69-83
pubmed: 23404579
Virology. 2018 May;518:45-54
pubmed: 29453058
Vet Microbiol. 2009 Nov 18;139(3-4):235-44
pubmed: 19595522
Pathogens. 2020 Nov 11;9(11):
pubmed: 33187194
Vaccine. 2000 Jan 18;18(13):1244-52
pubmed: 10649626
Vet Pathol. 2012 Nov;49(6):900-12
pubmed: 22461226
BMC Vet Res. 2012 Oct 03;8:182
pubmed: 23031319
Cell Rep. 2019 Nov 19;29(8):2243-2256.e4
pubmed: 31747598
Viruses. 2019 Aug 29;11(9):
pubmed: 31470568
PLoS One. 2019 Nov 14;14(11):e0224854
pubmed: 31725751
Front Vet Sci. 2019 Feb 20;6:38
pubmed: 30842948
J Vet Med B Infect Dis Vet Public Health. 2001 May;48(4):283-92
pubmed: 15129583
Arch Virol. 2001 Dec;146(12):2275-89
pubmed: 11811679
Vet Microbiol. 1996 Feb;48(3-4):325-35
pubmed: 9054128
Viral Immunol. 2010 Oct;23(5):457-66
pubmed: 20883160
Vaccines (Basel). 2021 Apr 09;9(4):
pubmed: 33918580
Vet Pathol. 1995 Nov;32(6):648-60
pubmed: 8592800
Vet Res. 2015 May 14;46:52
pubmed: 25971313
Arch Virol. 2019 Feb;164(2):457-472
pubmed: 30415389
Virus Res. 2015 May 4;203:56-65
pubmed: 25845944
Front Immunol. 2018 Oct 02;9:2299
pubmed: 30333837
Vet Rec. 2018 Apr 28;182(17):485
pubmed: 29472439
BMC Vet Res. 2019 Oct 16;15(1):342
pubmed: 31619295
Front Microbiol. 2017 Aug 28;8:1635
pubmed: 28894443
Eur J Immunol. 2020 Jan;50(1):97-109
pubmed: 31777067